AAPL315.32-0.90 (-0.28%) ▼|ABBV248.08-1.83 (-0.73%) ▼|ABT93.93-0.47 (-0.50%) ▼|ACN135.23-3.83 (-2.75%) ▼|ADBE223.64+0.99 (+0.44%) ▲|AMAT602.50+13.84 (+2.35%) ▲|AMD557.89+11.17 (+2.04%) ▲|AMGN363.39-0.23 (-0.06%) ▼|AMT168.59+3.59 (+2.18%) ▲|AMZN245.34-1.70 (-0.69%) ▼|AVGO399.97-1.14 (-0.28%) ▼|AXP350.58+3.86 (+1.11%) ▲|BA222.28-0.83 (-0.37%) ▼|BAC59.67+0.42 (+0.71%) ▲|BKNG178.39+2.87 (+1.64%) ▲|BLK1,036.11+16.43 (+1.61%) ▲|BMY57.58-0.36 (-0.62%) ▼|BNY151.92-0.34 (-0.22%) ▼|BRK-B493.71-1.74 (-0.35%) ▼|C140.79+1.22 (+0.87%) ▲|CAT952.41+14.02 (+1.49%) ▲|CL92.24+1.23 (+1.35%) ▲|CMCSA23.57+0.23 (+0.96%) ▲|COF201.52+1.42 (+0.71%) ▲|COP109.04+1.02 (+0.94%) ▲|COST916.25+3.28 (+0.36%) ▲|CRM163.32+0.82 (+0.50%) ▲|CSCO121.31+3.00 (+2.54%) ▲|CVS104.15+1.34 (+1.30%) ▲|CVX176.40+2.35 (+1.35%) ▲|DE586.86-6.04 (-1.02%) ▼|DHR199.05+3.07 (+1.57%) ▲|DIS95.62-0.55 (-0.57%) ▼|DUK125.48+0.22 (+0.18%) ▲|EMR138.88+1.08 (+0.78%) ▲|FDX314.69+3.85 (+1.24%) ▲|GD375.06+0.46 (+0.12%) ▲|GE359.27+0.23 (+0.06%) ▲|GEV1,091.57+16.31 (+1.52%) ▲|GILD129.83-5.01 (-3.72%) ▼|GM77.85+1.20 (+1.57%) ▲|GOOG355.03-1.21 (-0.34%) ▼|GOOGL357.18-1.71 (-0.48%) ▼|GS1,055.18-0.79 (-0.07%) ▼|HD343.30+4.57 (+1.35%) ▲|HON226.42+3.00 (+1.34%) ▲|IBM287.56-7.74 (-2.62%) ▼|INTC109.84-2.70 (-2.40%) ▼|INTU274.96+1.58 (+0.58%) ▲|ISRG406.78-4.77 (-1.16%) ▼|JNJ256.98-2.12 (-0.82%) ▼|JPM336.47+1.00 (+0.30%) ▲|KO83.49+0.86 (+1.04%) ▲|LIN529.79+4.23 (+0.80%) ▲|LLY1,188.58-28.37 (-2.33%) ▼|LMT523.22+4.96 (+0.96%) ▲|LOW211.63-1.37 (-0.64%) ▼|LRCX350.33-2.84 (-0.80%) ▼|MA526.74+3.54 (+0.68%) ▲|MCD274.60-1.89 (-0.68%) ▼|MDLZ58.83+0.53 (+0.91%) ▲|MDT83.87+1.48 (+1.80%) ▲|META669.21+37.73 (+5.97%) ▲|MMM157.52+2.18 (+1.40%) ▲|MO71.79+0.20 (+0.28%) ▲|MRK123.54-1.53 (-1.22%) ▼|MS222.28+0.15 (+0.07%) ▲|MSFT385.10+0.74 (+0.19%) ▲|MU979.30-12.34 (-1.24%) ▼|NEE87.96+0.86 (+0.99%) ▲|NFLX73.37-2.10 (-2.78%) ▼|NKE44.37+1.59 (+3.72%) ▲|NOW107.71-1.13 (-1.04%) ▼|NVDA210.96+8.18 (+4.03%) ▲|ORCL140.64-3.08 (-2.14%) ▼|PEP137.38-0.48 (-0.35%) ▼|PFE24.17-0.08 (-0.33%) ▼|PG147.04+0.19 (+0.13%) ▲|PLTR126.79-2.25 (-1.74%) ▼|PM181.62+0.45 (+0.25%) ▲|QCOM189.16-1.95 (-1.02%) ▼|RTX195.93+0.73 (+0.37%) ▲|SBUX106.01-0.40 (-0.38%) ▼|SCHW103.12+1.21 (+1.19%) ▲|SO95.61+0.44 (+0.46%) ▲|SPG218.77-0.94 (-0.43%) ▼|T21.13+0.37 (+1.77%) ▲|TMO527.05+2.34 (+0.45%) ▲|TMUS187.61+6.13 (+3.38%) ▲|TSLA407.76+1.21 (+0.30%) ▲|TXN311.46+2.93 (+0.95%) ▲|UBER74.54+0.19 (+0.26%) ▲|UNH424.62-7.06 (-1.64%) ▼|UNP286.96+1.92 (+0.67%) ▲|UPS112.47+1.73 (+1.56%) ▲|USB62.41+0.51 (+0.82%) ▲|V348.97+0.77 (+0.22%) ▲|VZ42.12+0.59 (+1.41%) ▲|WFC87.16+0.25 (+0.29%) ▲|WMT113.90+1.69 (+1.51%) ▲|XOM138.88+1.42 (+1.03%) ▲|AAPL315.32-0.90 (-0.28%) ▼|ABBV248.08-1.83 (-0.73%) ▼|ABT93.93-0.47 (-0.50%) ▼|ACN135.23-3.83 (-2.75%) ▼|ADBE223.64+0.99 (+0.44%) ▲|AMAT602.50+13.84 (+2.35%) ▲|AMD557.89+11.17 (+2.04%) ▲|AMGN363.39-0.23 (-0.06%) ▼|AMT168.59+3.59 (+2.18%) ▲|AMZN245.34-1.70 (-0.69%) ▼|AVGO399.97-1.14 (-0.28%) ▼|AXP350.58+3.86 (+1.11%) ▲|BA222.28-0.83 (-0.37%) ▼|BAC59.67+0.42 (+0.71%) ▲|BKNG178.39+2.87 (+1.64%) ▲|BLK1,036.11+16.43 (+1.61%) ▲|BMY57.58-0.36 (-0.62%) ▼|BNY151.92-0.34 (-0.22%) ▼|BRK-B493.71-1.74 (-0.35%) ▼|C140.79+1.22 (+0.87%) ▲|CAT952.41+14.02 (+1.49%) ▲|CL92.24+1.23 (+1.35%) ▲|CMCSA23.57+0.23 (+0.96%) ▲|COF201.52+1.42 (+0.71%) ▲|COP109.04+1.02 (+0.94%) ▲|COST916.25+3.28 (+0.36%) ▲|CRM163.32+0.82 (+0.50%) ▲|CSCO121.31+3.00 (+2.54%) ▲|CVS104.15+1.34 (+1.30%) ▲|CVX176.40+2.35 (+1.35%) ▲|DE586.86-6.04 (-1.02%) ▼|DHR199.05+3.07 (+1.57%) ▲|DIS95.62-0.55 (-0.57%) ▼|DUK125.48+0.22 (+0.18%) ▲|EMR138.88+1.08 (+0.78%) ▲|FDX314.69+3.85 (+1.24%) ▲|GD375.06+0.46 (+0.12%) ▲|GE359.27+0.23 (+0.06%) ▲|GEV1,091.57+16.31 (+1.52%) ▲|GILD129.83-5.01 (-3.72%) ▼|GM77.85+1.20 (+1.57%) ▲|GOOG355.03-1.21 (-0.34%) ▼|GOOGL357.18-1.71 (-0.48%) ▼|GS1,055.18-0.79 (-0.07%) ▼|HD343.30+4.57 (+1.35%) ▲|HON226.42+3.00 (+1.34%) ▲|IBM287.56-7.74 (-2.62%) ▼|INTC109.84-2.70 (-2.40%) ▼|INTU274.96+1.58 (+0.58%) ▲|ISRG406.78-4.77 (-1.16%) ▼|JNJ256.98-2.12 (-0.82%) ▼|JPM336.47+1.00 (+0.30%) ▲|KO83.49+0.86 (+1.04%) ▲|LIN529.79+4.23 (+0.80%) ▲|LLY1,188.58-28.37 (-2.33%) ▼|LMT523.22+4.96 (+0.96%) ▲|LOW211.63-1.37 (-0.64%) ▼|LRCX350.33-2.84 (-0.80%) ▼|MA526.74+3.54 (+0.68%) ▲|MCD274.60-1.89 (-0.68%) ▼|MDLZ58.83+0.53 (+0.91%) ▲|MDT83.87+1.48 (+1.80%) ▲|META669.21+37.73 (+5.97%) ▲|MMM157.52+2.18 (+1.40%) ▲|MO71.79+0.20 (+0.28%) ▲|MRK123.54-1.53 (-1.22%) ▼|MS222.28+0.15 (+0.07%) ▲|MSFT385.10+0.74 (+0.19%) ▲|MU979.30-12.34 (-1.24%) ▼|NEE87.96+0.86 (+0.99%) ▲|NFLX73.37-2.10 (-2.78%) ▼|NKE44.37+1.59 (+3.72%) ▲|NOW107.71-1.13 (-1.04%) ▼|NVDA210.96+8.18 (+4.03%) ▲|ORCL140.64-3.08 (-2.14%) ▼|PEP137.38-0.48 (-0.35%) ▼|PFE24.17-0.08 (-0.33%) ▼|PG147.04+0.19 (+0.13%) ▲|PLTR126.79-2.25 (-1.74%) ▼|PM181.62+0.45 (+0.25%) ▲|QCOM189.16-1.95 (-1.02%) ▼|RTX195.93+0.73 (+0.37%) ▲|SBUX106.01-0.40 (-0.38%) ▼|SCHW103.12+1.21 (+1.19%) ▲|SO95.61+0.44 (+0.46%) ▲|SPG218.77-0.94 (-0.43%) ▼|T21.13+0.37 (+1.77%) ▲|TMO527.05+2.34 (+0.45%) ▲|TMUS187.61+6.13 (+3.38%) ▲|TSLA407.76+1.21 (+0.30%) ▲|TXN311.46+2.93 (+0.95%) ▲|UBER74.54+0.19 (+0.26%) ▲|UNH424.62-7.06 (-1.64%) ▼|UNP286.96+1.92 (+0.67%) ▲|UPS112.47+1.73 (+1.56%) ▲|USB62.41+0.51 (+0.82%) ▲|V348.97+0.77 (+0.22%) ▲|VZ42.12+0.59 (+1.41%) ▲|WFC87.16+0.25 (+0.29%) ▲|WMT113.90+1.69 (+1.51%) ▲|XOM138.88+1.42 (+1.03%) ▲|
27.5 C
New York
Saturday, July 11, 2026

Tag: research

newssourceFORcompanyinformationcontent1releasesmarket

MarketsandMarkets’ 360Quadrants Recognizes Top Startups and SMEs in the PFAS Testing Quadrant Report 2025

DELRAY BEACH, Fla., June 6, 2025 /PRNewswire/ -- 360Quadrants has released its latest PFAS testing Startups/SMEs Companies Assessment, 2025, recognizing key players, including both global...

Healthcare Simulation Market worth US$7.23 billion by 2030 with 15.6% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., June 6, 2025 /PRNewswire/ -- The global Healthcare Simulation Market, valued at US$3.00 billion in 2024 stood at US$3.50 billion in 2025...

Global Cyber Range Market Set to Grow at 9.0% CAGR, Fueled by Rising Cybersecurity Skill Gaps: Valuates Reports

Cyber Range Market is Segmented by Type (Cloud-based, On-premise, Hybrid), by Application (Training Purpose, Network Testing). BANGALORE, India, June 6, 2025 /PRNewswire/ -- The Global...

LNG Terminals Market worth $13.15 billion by 2030 | MarketsandMarkets™

DELRAY BEACH, Fla., June 6, 2025 /PRNewswire/ -- The global LNG Terminals Market is anticipated to grow from estimated USD 7.86 billion in 2025 to...

Functional Gummies Market to Hit USD 2.4 Billion by 2030, Driven by Vegan & Vitamin Gummy Demand | Valuates Reports

BANGALORE, India, June 6, 2025 /PRNewswire/ -- Functional Gummies Market is Segmented by Type (Gelatin Gummies, Vegan Gummies), by Application (Vitamin Gummies, DHA and Omega-3...

Hospital PMI® at 52%; May 2025 Hospital ISM® Report On Business®

TEMPE, Ariz., June 6, 2025 /PRNewswire/ -- Economic activity in the hospital subsector expanded in May for the 21st consecutive month and the 38th...

Sobi and Apellis: Aspaveli®/Empaveli® Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases

STOCKHOLM, June 6, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase...

Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

PRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today spotlights the efforts of Ellen Kim, M.D., Lead Principal Investigator for the Company’s Phase 3 FLASH (1 and 2) studies in early stage cutaneous T-cell lymphoma (CTCL), in advancing HyBryte™ (synthetic hypericin) as a potential new therapy for patients living with mycosis fungoides (MF), the most common form of CTCL.

Carlsberg lays on the perfect ride to surprise taxi drivers during the UEFA Nations League Finals™ 2025

9 in 10 taxi drivers consider themselves football fans, yet 91% have chosen to work when a sporting moment is on despite wanting to...

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The data were presented as part of a late-breaking session at the European Renal Association (ERA) Congress.

Lung Cancer Patient Advocates Join World’s Largest Oncology Conference

LiveLung 'ASCO Scholars' Share Experience at Educational Meeting CHICAGO, June 6, 2025 /PRNewswire/ -- Six lung cancer patients and one care partner were selected as...

AMERICA’S SWEETHEARTS – THE DALLAS COWBOYS CHEERLEADERS – BECOME CHARLOTTE TILBURY DARLINGS

COMBINING CONFIDENCE AND CHEER, CHARLOTTE TILBURY ANNOUNCES GROUNDBREAKING NEW PARTNERSHIP WITH THE DALLAS COWBOYS CHEERLEADERS! AS THE DCC'S BEAUTY PARTNER, CHARLOTTE TILBURY WILL BRING THE...

Insurers Retreat as 2025 Wildfire Risk Reaches Dangerous Levels

New report reveals 150,000+ uninsured households in California's highest-risk areas as spring fire conditions hit 10-year records MONTREAL, June 6, 2025 /PRNewswire/ -- Deep Sky, the...

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company’s Board of Directors.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsResearch

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers